Barrington Research Maintains Outperform on Concentrix, Lowers Price Target to $38

Benzinga Newsdesk www.benzinga.com Negative 95.9%

Neg 95.9% Neu 0% Pos 0%

Barrington Research analyst Vincent Colicchio maintains Concentrix (NASDAQ:CNXC) with a Outperform and lowers the price target from $62 to $38.